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AbstrAct:
Aging is one of the major risk factors of cancer. The onset of cancer can be postponed 
by pharmacological and dietary anti-aging interventions. We recently found in yeast 
cellular models of aging that lithocholic acid (LCA) extends longevity. Here we show 
that, at concentrations that are not cytotoxic to primary cultures of human neurons, 
LCA kills the neuroblastoma (NB) cell lines BE(2)-m17, SK-n-SH, SK-n-MCIXC and Lan-
1. In BE(2)-m17, SK-n-SH and SK-n-MCIXC cells, the LCA anti-tumor effect is due to 
apoptotic cell death. In contrast, the LCA-triggered death of Lan-1 cells is not caused 
by apoptosis. While low concentrations of LCA sensitize BE(2)-m17 and SK-n-MCIXC 
cells to hydrogen peroxide-induced apoptotic cell death controlled by mitochondria, 
these LCA concentrations make primary cultures of human neurons resistant to such 
a form of cell death. LCA kills BE(2)-m17 and SK-n-MCIXC cell lines by triggering not 
only the intrinsic (mitochondrial) apoptotic cell death pathway driven by mitochondrial 
outer membrane permeabilization and initiator caspase-9 activation, but also the 
extrinsic (death receptor) pathway of apoptosis involving activation of the initiator 
caspase-8. Based on these data, we propose a mechanism underlying a potent and 
selective anti-tumor effect of LCA in cultured human NB cells. Moreover, our finding 
that LCA kills cultured human breast cancer and rat glioma cells implies that it has a 
broad anti-tumor effect on cancer cells derived from different tissues and organisms.
IntroductIon
Due to a multistep nature of the tumorigenesis 
process whose progression and completion requires an 
extended period of time, incidence rates of many cancers 
increase with age [1-3]. Therefore, cancer is considered 
as a disease associated with aging [3-7]. In the generally 
accepted paradigm of the relationship between aging 
and cancer, they share common aetiology (i.e., an age-
related progressive accumulation of cellular damage) and 
have coalescent mechanisms [4-9]. A body of evidence 
supports the validity of this paradigm. First, aging and 
cancer indeed have convergent underlying mechanisms. 
They include: 1) a longevity-defining signaling network 
that integrates the pro-aging AMP-activated protein 
kinase/target of rapamycin (AMPK/TOR), cAMP/protein 
kinase A  (cAMP/PKA)  and  insulin/insulin-like  growth 
factor 1 (IGF-1) signaling pathways and also incorporates 
a sirtuin-governed protein deacetylation module [4-14]; 
2) a cytoprotective process of autophagy [8-9,15-23]; 
and 3) tricarboxylic acid cycle, respiration, and reactive 
oxygen  species  (ROS)  production  and  detoxification Oncotarget 2011; 2:  761 - 782 762 www.impactjournals.com/oncotarget
in mitochondria [24-32]. Second, some of the proteins 
implemented in such convergent mechanisms could 
function as oncoproteins, whereas others act as tumor 
suppressor proteins [3-6,10-21,24-33]. Third, certain 
pharmacological and dietary interventions exhibit both 
anti-aging and anti-cancer effects by modulating the 
longevity signaling network that integrates the AMPK/
TOR,  cAMP/PKA  and  insulin/IGF-1  pathways  and 
incorporates the sirtuin-governed protein deacetylation 
module [4-7,10-14,33-52].
The interplay between aging and cancer is more 
complex than only sharing common aetiology and having 
convergent mechanisms. In some situations aging and 
cancer can have antagonistic aetiologies and divergent 
mechanisms [5,8,9,53-65]. Indeed, the age-dependent 
accumulation of DNA damage and mutations in normal 
somatic cells (especially in adult stem and progenitor 
cells) triggers telomere shortening and/or a gradual rise 
in the expression of the INK4a/ARF locus encoding the 
p16INK4a  and  p14ARF/p19ARF  tumor  suppressor 
proteins [53-56,58,62]. Both these processes reduce the 
proliferative potential of normal somatic cells, thereby 
promoting cellular senescence, causing a decline in tissue 
regeneration and repair, impairing tissue homeostasis, 
and ultimately accelerating cellular and organismal aging 
[53-58]. While both telomere shortening and enhanced 
expression of INK4a/ARF display pro-aging effects in 
normal somatic cells, they exhibit potent anti-cancer 
effects in tumor cells by reducing their proliferative 
potential [53-62]. Hence, an anti-cancer intervention 
that can limit the excessive proliferation of tumor cells 
by inhibiting telomerase or activating expression of 
INK4a/ARF could have a pro-aging effect on cellular and 
organismal levels [5,8,9,55-59,62-65].
The complexity of the interplay between aging 
and cancer is further underscored by the recent findings 
implying that tumor cells in the epithelia of breast 
cancers can cause “accelerated aging” of adjacent 
normal fibroblasts by stimulating their intracellular ROS 
production [66-77]. In response to the resulting oxidative 
stress these fibroblasts establish a pro-aging pattern by 
activating aerobic glycolysis and autophagic degradation, 
thereby providing epithelial cancer cells within the 
tumor microenvironment with lactate, ketone bodies and 
glutamine [67,70,76-79]. These catabolic and anabolic 
substrates support proliferation of epithelial cancer cells 
and, thus, accelerate tumor growth, progression and 
metastasis [67,76,77]. Further emphasizing the complexity 
of the relationship between aging and cancer, this model 
of breast cancer as an “accelerated host aging” disease 
defines  autophagy  (a  cytoprotective  anti-aging  cellular 
process [8,9,15-23]) within cancer-associated fibroblasts 
as a pro-cancer process that supports the growth of already 
established tumors [67,76,77]. In contrast, by preventing 
initiation of some cancers, autophagy operates as an 
anti-cancer process prior to tumor establishment [8,9,15-
23,80-85].
We found that lithocholic acid (LCA), a bile 
acid,  delays  chronological  aging  of  yeast  [86]  known 
to mimic aging of postmitotic mammalian cells (e.g., 
neurons) [87-89]. In yeast, LCA extends longevity not 
by  attenuating  the  pro-aging  AMPK/TOR  and  cAMP/
PKA  signaling  pathways  [86],  both  of  which  operate 
as pro-cancer pathways in mice and humans [4-14]. 
Furthermore, we revealed that the longevity-extending 
effect of LCA in chronologically aging yeast depends on 
autophagy (Kyryakov et al., manuscript in preparation), 
a cytoprotective anti-aging process that in different 
situations can play either an anti-cancer or a pro-cancer 
role [8,9,15-23,80-85]. Moreover, LCA extends yeast 
chronological life span by altering the age-related 
dynamics  of  mitochondria-confined  respiration  and 
ROS production [86], both of which are integrated into 
convergent mechanisms underlying aging and cancer 
[24-32]. Additionally, we found that in chronologically 
aging yeast LCA slows down telomere shortening (Iouk 
et al., unpublished data), a pro-aging process that exhibits 
an anti-cancer effect [53-62]. Besides, we demonstrated 
that LCA not only extends the chronological life span 
of quiescent yeast but also hinders cellular quiescence 
and senescence by delaying replicative aging of yeast 
(Lindsay et al., manuscript in preparation), which mimics 
aging of mitotically active mammalian cells [87-89]. In 
sum, these findings imply that in yeast models of aging 
of mitotically active and inactive mammalian cells LCA 
extends longevity by modulating several processes 
integrated into either convergent or divergent mechanisms 
underlying aging and cancer.
We therefore sought to examine if LCA exhibits 
an anti-tumor effect in cultured human cancer cells 
by activating certain anti-cancer processes that may 
play an essential role in cellular aging. As a model for 
assessing such effect of LCA, we choose several cell 
lines of the human neuroblastoma (NB) tumor. NB 
is the most commonly diagnosed extra-cranial solid 
tumor among children [90-92]. All NBs originate from 
primordial neuroblast cells that eventually differentiate 
into the adrenal medulla and early sympathetic nervous 
system [92-95]. In over 70% of all cases studied so far, 
NBs metastasize to other tissues [90-95]. Although most 
patients diagnosed with non-metastasizing NBs have 
been reported to be cured, only less than 40% of those 
with cancerous migration to other tissues survive despite 
rigorous chemotherapeutic and surgical treatment [92]. 
The recurrent high-risk NB patients with an often fatal 
prognosis frequently contain the following two genetic 
abnormalities: 1) amplification of the MYCN gene [96-
98] encoding a transcription factor involved in growth, 
cell metabolism and division [99]; and 2) deletion of 
the short arm of chromosome 1p [100], which reduces 
expression of numerous tumour-suppressing genes [101-
104]. One of the main challenges of combating high-risk Oncotarget 2011; 2:  761 - 782 763 www.impactjournals.com/oncotarget
recurring NBs is the use of non-toxic agents that not only 
prevent tumor metastasis, but also eliminate the primary 
tumor. Currently, NBs are treated with a combination of 
the chemotherapeutic drugs that cause apoptotic death 
of malignant cancer cells by inducing DNA strand 
intercalation (doxorubicin, cisplatin, cyclophosphamide 
and topotecan), DNA strand breaks (epipodophyllotoxins) 
or mitotic inhibition (vincristine) [105-111]. Noteworthy, 
all these anti-NB drugs stimulate the release of significant 
amount of ROS from mitochondria [107-111].
Here we show that LCA has a potent anti-tumor effect 
in four lines of cultured human NB cells. We demonstrate 
that  this  anti-aging  compound  kills  three  of  them  by 
causing apoptotic cell death. Our mechanistic studies of 
the apoptosis-based death of NB cell cultures exposed 
to LCA provide evidence that this bile acid triggers both 
the intrinsic and extrinsic apoptotic death pathways by 
binding to the cell surface and initiating the converging 
intracellular cascades activating caspases-3, -6, -8 and -9. 
We propose a model for a mechanism underlying a potent 
and specific anti-tumor effect of LCA in cultured human 
NB cells. We also show that LCA has a broad anti-tumor 
effect on cultured cancer cells derived from different 
tissues and organisms.
results
lcA selectively kills cultured human nb cells
The MTT (3-(4,5-dimethylthiozol-2-yl)-2,5-
diphenyltetrazolium bromide) assay is widely used 
to determine viability of cultured mammalian cells 
following drug treatment [112-116]. In this assay, only 
viable, metabolically active cells are able to reduce the 
yellow tetrazolium salt of MTT to form a purple formazan 
product. Thus, the percentage of viable cells in the MTT 
assay is calculated as the proportion of the cell population 
displaying a detectable level of redox potential. Using this 
assay, we found that LCA exhibits a potent and selective 
anti-tumor effect in several lines of cultured human 
NB cells. In fact, this bile acid killed the NB cell lines 
Figure 1: lcA selectively kills all four tested lines of cultured human nb cells - by causing an apoptosis-based death 
of be(2)-m17, sK-n-sH and sK-n-McIXc lines, but triggering a non-apoptotic death of lan-1 line. In A, the percentage 
of viable cells was calculated as a portion of their population displaying a detectable level of redox potential which was monitored using 
the MTT (3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide)-based CellTiter 96 Non-Radioactive Cell Proliferation Assay. 
In B, the fluorescent dye Hoechst was used to visualize chromatin in various cell cultures and the percentage of viable non-apoptotic cells 
carrying intact, non-fragmented nuclei containing non-condensed chromatin was calculated; dead apoptotic cells carried fragmented nuclei 
containing condensed chromatin, a hallmark event of apoptotic death. A. LCA kills NB cell lines BE(2)-m17, SK-n-SH, SK-n-MCIXC and 
Lan-1 if used at concentrations that are not cytotoxic or only mildly cytotoxic (as in case of Lan-1) to primary cultures of human neurons. 
B. The NB cell line SK-n-MCIXC is the most sensitive to LCA-induced apoptotic death; two other lines, BE(2)-m17 and SK-n-SH, exhibit 
much higher sensitivity to LCA-induced apoptotic death than primary cultures of human neurons or the NB cell line Lan-1. Data are 
presented as means ± SD (n = 4-6).
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Figure 2: lcA increases sensitivity of cultured human nb cells to hydrogen peroxide-induced apoptotic cell death. 
A. If used at concentrations below 100 µM, LCA protects primary cultures of human neurons against mitochondria-controlled apoptosis 
induced in response to exogenously added 0.1 mM hydrogen peroxide. B and C. In contrast, if used at concentrations below 100 µM, LCA 
greatly enhances the susceptibility of cultured human NB cell lines BE(2)-m17 (B) and SK-n-MCIXC (C) to such hydrogen peroxide-
induced form of cell death. While 75 μM LCA causes apoptotic death of all or most of the cells of BE(2)-m17 and SK-n-MCIXC exposed to 
0.1 mM hydrogen peroxide (B and C, respectively), in this concentration it increases the resistance of primary cultures of human neurons to 
such form of cell death (A). Nuclear fragmentation and chromatin condensation were visualized with the fluorescent dye Hoechst and were 
used as a measure of the efficacy of hydrogen peroxide-induced apoptotic cell death. Each panel shows two datasets for the same cell type. 
One dataset is for cell aliquots treated with 0.1 mM hydrogen peroxide, whereas the other dataset is for cell aliquots remained untreated. For 
each cell culture, the percentage of viable non-apoptotic cells carrying intact, non-fragmented nuclei containing non-condensed chromatin 
was calculated. Data are presented as means ± SD (n = 3-5).
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BE(2)-m17, SK-n-SH, SK-n-MCIXC and Lan-1 if used 
at concentrations that were not cytotoxic or only mildly 
cytotoxic (as in case of Lan-1) to primary cultures of 
human neurons (Fig. 1A).
Chromatin condensation and nuclear fragmentation 
are hallmark events of apoptosis that are not seen under 
any other modes of cell death [117-122]. We used the 
fluorescent dye Hoechst to visualize chromatin in various 
NB cell cultures and in primary cultures of human 
neurons exposed to LCA or remained untreated. For each 
cell culture, we calculated the percentage of viable non-
apoptotic cells carrying intact, non-fragmented nuclei 
containing non-condensed chromatin. Dead apoptotic 
cells  carried  condensed  and/or  fragmented  nuclei.  Our 
data imply that if LCA is used at concentrations that 
are not cytotoxic to primary cultures of human neurons, 
it selectively kills the NB cell lines BE(2)-m17, SK-n-
SH and SK-n-MCIXC by causing their apoptotic death. 
We  found  that  SK-n-MCIXC  is  the  most  sensitive  (as 
compared to other NB cell lines tested and especially as 
compared to primary cultures of human neurons) to the 
apoptotic death induced by LCA (Fig. 1B), as it is to the 
MTT-monitored cytotoxic effect of this bile acid (Fig. 
1A).  Furthermore,  although  BE(2)-m17  and  SK-n-SH 
were less sensitive to LCA-induced apoptosis than SK-
n-MCIXC, they exhibited much higher sensitivity to such 
form of cell death (Fig. 1B) - and to the MTT-monitored 
cytotoxic effect of LCA (Fig. 1A) - than primary cultures 
of human neurons or the NB cell line Lan-1. Importantly, 
although at the concentrations of LCA exceeding 200 
µM the NB cell line Lan-1 was more sensitive to the 
MTT-monitored cytotoxic effect of LCA than primary 
cultures of human neurons (Fig. 1A), this cell line did not 
exhibit higher sensitivity to LCA-induced apoptotic cell 
death than primary neuron cultures (Fig. 1B). Thus, LCA 
selectively kills Lan-1 cells via a non-apoptotic cell death 
mechanism.
lcA sensitizes two nb cell lines to hydrogen 
peroxide-induced apoptotic cell death
Exogenously  added  hydrogen  peroxide  has  been 
shown to cause mitochondria-controlled apoptotic cell 
death in a variety of cultured eukaryotic cells [123-128]. 
Our data imply that LCA protects primary cultures of human 
neurons, but not cultured human NB cell lines BE(2)-m17 
or SK-n-MCIXC, against apoptosis induced in response to 
exogenously added 0.1 mM hydrogen peroxide (Fig. 2). 
In these experiments, chromatin condensation and nuclear 
fragmentation were visualized with the fluorescent dye 
Hoechst  and  were  used  as  a  measure  of  the  efficacy 
of hydrogen peroxide-induced apoptotic cell death. 
Importantly, LCA greatly enhanced the susceptibility of 
BE(2)-m17 and SK-n-MCIXC to such a mitochondria-
controlled form of cell death (compare Figs. 2B and 2C 
to Fig. 2A), even if it was used at concentrations that in 
the absence of hydrogen peroxide did not compromise 
their viability (compare Figs. 2B and 2C to Figs. 1A and 
1B). Of note, while 75 μM LCA caused apoptotic death 
of all or most of the BE(2)-m17 and SK-n-MCIXC cells 
exposed to hydrogen peroxide, this concentration of LCA 
significantly increased the resistance of primary cultures 
of human neurons to the hydrogen peroxide-induced form 
of mitochondria-controlled apoptotic death (compare Fig. 
2A to Figs. 2B and 2C). Based on these observations, it 
seems likely that an exposure of a mixed population of at 
least these two NB cell lines and non-cancerous neurons 
to low concentrations of simultaneously added hydrogen 
peroxide and LCA may concurrently 1) kill all or most 
of NB cells by causing their apoptotic cell death; and 
2) promote the viability of non-cancerous neurons by 
increasing their resistance to hydrogen peroxide-induced 
apoptosis.
lcA triggers the intrinsic (mitochondrial) 
pathway of apoptotic death in two nb cell lines
As described above, LCA selectively kills the NB cell 
lines BE(2)-m17 and SK-n-MCIXC by causing apoptosis 
and enhances their susceptibility to a hydrogen peroxide-
induced form of mitochondria-controlled apoptosis. We 
therefore sought to investigate if LCA kills these two NB 
cell lines by activating the intrinsic apoptotic cell death 
pathway. The key feature of such a pathway is mitochondrial 
outer membrane permeabilization (MOMP), which leads 
to the release of cytochrome c (and several other pro-
apoptotic proteins) from the mitochondrial intermembrane 
space  into  the  cytosol  [129-131].  Following  its  efflux 
from mitochondria, cytochrome c binds an apoptotic 
protease-activating factor 1 (APAF-1) monomer whose 
oligomerization into the heptameric apoptosome complex 
recruits caspase-9 and ultimately activates this initiator 
caspase [119,131-133]. We found that LCA significantly 
increases  caspase-9  activity  in  BE(2)-m17  and  SK-n-
MCIXC (Fig. 3). Furthermore, in both these NB cell lines 
LCA caused the fragmentation of a mitochondrial network 
(Figs.  4A  and  4B).  Such  fragmentation  is  one  of  the 
earliest events of the mitochondrial pathway of apoptosis; 
it occurs before caspase-9 activation, around the point 
of MOMP and cytochrome c efflux from mitochondria 
[119,129-131,134,135]. Moreover, in both these cell lines 
LCA triggered the dissipation of the electrochemical 
potential across the inner mitochondrial membrane (Figs. 
4C and 4D). The gradual dissipation and eventual loss 
of mitochondrial transmembrane potential is a hallmark 
event of mitochondria-dependent apoptotic cell death; it 
follows MOMP and occurs in both caspase-dependent and 
caspase-independent fashion [119,130,131,136-139]. Of 
note, the higher LCA-induced activity of caspase-9 (Fig. 
3) and efficacies of both LCA-promoted mitochondrial Oncotarget 2011; 2:  761 - 782 766 www.impactjournals.com/oncotarget
fragmentation and LCA-triggered mitochondrial inner 
membrane depolarization (Figs. 4B and 4D) observed 
in  SK-n-MCIXC  cells,  as  compared  to  those  seen  in 
BE(2)-m17  cells,  correlated  with  the  higher  sensitivity 
of SK-n-MCIXC (as compared to that of BE(2)-m17) to 
the cytotoxic, apoptotic cell death-inducing and hydrogen 
peroxide-sensitizing effects of LCA (Figs. 1 and 2).
Importantly, although LCA stimulated caspase-9 in 
BE(2)-m17 and SK-n-MCIXC cells, it did not increase 
caspase-9 activity in Lan-1 cells (Fig. 3). Furthermore, 
if used at a concentration (i.e.,  150  μM  or  175  μM) 
that caused mitochondrial fragmentation in most or all 
BE(2)-m17 and SK-n-MCIXC cells, LCA did not stimulate 
such fragmentation in Lan-1 cells (Fig. 4B). Moreover, 
if used at a concentration (i.e., 150 μM or 200 μM) that 
triggered mitochondrial inner membrane depolarization 
in most or all BE(2)-m17 and SK-n-MCIXC cells, LCA 
did not cause such depolarization in Lan-1 cells (Fig. 4D). 
These findings further validate our conclusion (see above) 
that LCA kills Lan-1 cells via a non-apoptotic cell death 
mechanism.
lcA increases activities of caspases-3 and -6 in 
two nb cell lines
The apoptosome-driven activation of caspase-9 
during mitochondria-controlled apoptosis initiates a 
stepwise activation of several executioner caspases. In one 
scenario, the caspase-9-dependent proteolytic activation 
of the executioner caspases-3 and -7 is followed by the 
caspase-3-driven proteolytic activation of the executioner 
caspases-2 and -6 and then by the caspase-6-enabled 
proteolytic activation of the executioner caspase-10; when 
all these caspases become activated, they complete the 
demolition phase of the mitochondria-controlled apoptotic 
program by cleaving their respective protein substrates 
and producing the morphological features characteristic 
of apoptotic cell death [119,130,131,140,141]. In 
another scenario, caspase-6 is activated independent of 
caspase-3 [142-151], either by caspase-1 [148] or through 
intramolecular self-cleavage [152-154], and does not 
induce apoptosis [143,144,149,152,155].
We found that LCA increases caspase-3 activity in 
BE(2)-m17 and SK-n-MCIXC (Fig. 5A) by promoting a 
proteolytic conversion of a zymogen pro-caspase-3 form 
into an active 17 kDa form (Fig. 5B). Importantly, the 
anti-tumor effect of LCA in these two cell lines was due in 
part to its ability to activate caspase-3. In fact, z-DEVD-
fmk,  a  potent  and  specific  inhibitor  of  caspase-3  (Fig. 
5D), significantly reduced the efficacy with which LCA 
caused selective killing of BE(2)-m17 and SK-n-MCIXC 
cells  (Fig.  5E).  The  observed  incomplete  reduction 
by z-DEVD-fmk of the anti-tumor efficacy of LCA in 
BE(2)-m17 and SK-n-MCIXC (Fig. 5E) suggests that the 
LCA-triggered, mitochondria-driven apoptotic death of 
both these cell lines could be due not only to a caspase-
dependent mechanism, but also to a caspase-independent 
decline in mitochondrial function, which may lead to the 
observed LCA-dependent mitochondrial fragmentation 
and loss of mitochondrial transmembrane potential (Fig. 
4).  In  BE(2)-m17  and  SK-n-MCIXC  cells,  LCA  also 
elevated caspase-6 activity (Fig. 6A) and promoted a 
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proteolytic conversion of a zymogen pro-caspase-6 form 
of this caspase into its large (p20) and small (p10) subunits 
(Fig. 6B) known to assemble into an enzymatically active 
heterotetramer of two p20 and two p10 [152,156]. Of note, 
the  different  efficacies  of  the  LCA-induced  proteolytic 
activation of caspase-3 and caspase-6 seen in BE(2)-m17 
and SK-n-MCIXC cells (Figs. 5 and 6) correlated with 
their dissimilar sensitivities to the cytotoxic, apoptosis-
inducing and hydrogen peroxide-sensitizing effects of 
LCA (Figs. 1 and 2). Furthermore, even if used at a higher 
concentration (i.e., 250 μM) than the ones causing the 
highest extent of the LCA-induced proteolytic activation 
of caspase-3 and caspase-6 (i.e.,  125  μM  or  150  μM) 
in  SK-n-MCIXC  and  BE(2)-m17  cells,  LCA  did  not 
promote their proteolysis-driven activation in Lan-1 cells 
(Figs. 5 and 6), whose LCA-induced death was not due to 
apoptosis (see above).
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Figure 4: In cultured human nb cell lines be(2)-m17 and sK-n-McIXc (but not in lan-1), lcA causes mitochondrial 
fragmentation and triggers the dissipation of the electrochemical potential across the inner mitochondrial membrane. 
A. Mitochondrial morphology in NB cells treated with LCA or remained untreated was visualized using MitoTracker Red CMXRos as 
described in Materials and Methods. Cells were viewed using fluorescence microscopy. B. The percentage of cells displaying fragmented 
mitochondria was calculated. C. The mitochondrial membrane potential (∆Ψ) in NB cells treated with LCA or remained untreated was 
measured using tetramethylrhodamine ethyl ester (TMRE) as described in Materials and Methods; the extent of reversible sequestration of 
TMRE by mitochondria is proportional to the value of ∆Ψ. Cells were incubated with 50 nM TMRE for 20 min and directly viewed using 
fluorescence microscopy. D. The percentage of TMRE-positive cells displaying a detectable level of ∆Ψ was calculated. Data in B and D 
are presented as means ± SD (n = 3-4).Oncotarget 2011; 2:  761 - 782 768 www.impactjournals.com/oncotarget
lcA increases the activity of the initiator 
caspase-8 in two nb cell lines
The proteolytic cleavage of pro-caspase-3 and the 
resulting increase of caspase-3 activity can be triggered 
not only through the intrinsic (mitochondrial) apoptotic 
death pathway but also through the extrinsic (death 
receptor) pathway of apoptosis. This extrinsic pathway is 
initiated when specific extracellular death ligands cause 
the ligation of death receptors in the plasma membrane, 
thus triggering a process eventually leading to activation 
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Figure 5: lcA increases activity of the executioner caspase-3 in cultured human nb cell lines be(2)-m17 and sK-
n-McIXc (but not in lan-1) by stimulating a proteolytic conversion of its zymogen pro-caspase-3 form into its 
enzymatically active 17 kda form. The anti-tumor effect of LCA in BE(2)-m17 and SK-n-MCIXC cell lines is due in part to its ability 
to increase caspase-3 activity. A and D. Specific activity of caspase-3 was measured in NB cells treated with LCA and/or z-DEVD-fmk 
(a potent and specific inhibitor of caspase-3) or remained untreated as described in Materials and Methods and expressed in picomoles of 
fluorescent compound 7-amino-4-trifluoromethyl coumarin released per microgram of protein per minute. B and C. Pro-caspase-3 cleavage 
assay was carried out as described in Materials and Methods. E. The fluorescent dye Hoechst was used to visualize chromatin in NB cell 
cultures treated with LCA and/or z-DEVD-fmk or remained untreated. For each cell culture, the percentage of viable non-apoptotic cells 
carrying intact, non-fragmented nuclei containing non-condensed chromatin was calculated; dead apoptotic cells carried fragmented nuclei 
containing condensed chromatin, a hallmark event of apoptotic death. Data in A, D and E are presented as means ± SD (n = 3-4); **p<0.01; 
***p<0.001.Oncotarget 2011; 2:  761 - 782 769 www.impactjournals.com/oncotarget
of the initiator caspase-8 [119,131]. In addition to its 
role in the proteolytic activation of caspase-3, activated 
in response to death receptor ligation caspase-8 can also 
cleave and activate the BH3-only protein BID, thereby 
causing  MOMP  and  initiating  the  intrinsic  pathway  of 
apoptosis [119,131,157,158].
We  found  that  LCA  significantly  increases  the 
activity  of  caspase-8  in  BE(2)-m17  and  SK-n-MCIXC 
(Fig. 7). As it was observed for caspases-3, -6 and -9 
(Figs. 5A, 6A and 3, respectively), the extent to which 
caspase-8 was activated by LCA in these two cell lines 
(Fig. 7) correlated with the degree of their sensitivity to 
the cytotoxic, apoptosis-inducing and hydrogen peroxide-
sensitizing effects of LCA (Figs. 1 and 2). Importantly, 
unlike the stimulating effect of LCA on caspase-8 seen 
in  BE(2)-m17  and  SK-n-MCIXC  cells,  this  bile  acid 
did not stimulate caspase-8 activity in Lan-1 cells (Fig. 
7).  These  findings  suggest  that  LCA  could  kill  both 
BE(2)-m17  and  SK-n-MCIXC  cell  lines  by  activating 
not only the intrinsic apoptotic death pathway dependent 
on the initiator caspase-9, but also the extrinsic pathway 
of apoptotic death driven by the initiator caspase-8. We 
therefore propose that the LCA-dependent activation of 
caspase-8 seen in BE(2)-m17 and SK-n-MCIXC cells (Fig. 
7) could be responsible not only for the direct proteolytic 
activation of caspase-3 (Figs. 5A and 5B), but also for 
MOMP (perhaps, due to BID cleavage by caspase-8) and 
the resulting initiation of the intrinsic apoptotic death 
pathway observed in these NB cells (Figs. 3 and 4). These 
caspase-8-driven events in BE(2)-m17 and SK-n-MCIXC 
cells are expected to enhance the extent of their demise in 
response to LCA treatment.
Figure 6: lcA increases activity of the executioner caspase-6 in cultured human nb cell lines be(2)-m17 and sK-n-
McIXc (but not in lan-1) by stimulating a proteolytic conversion of a zymogen pro-caspase-6 form into its large and 
small subunits known to assemble into an enzymatically active heterotetramer consisted of the two of each subunits. 
A. Specific activity of caspase-6 was measured as described in Materials and Methods and expressed in picomoles of fluorescent compound 
7-amino-4-trifluoromethyl coumarin released per microgram of protein per minute. B. Pro-caspase-6 cleavage assay was carried out as 
described in Materials and Methods. The anti-human-caspase-6 mouse monoclonal IgG1 clone B93-4 antibodies raised against amino 
acids 271-285 (Pharmingen) were used; these antibodies specifically recognize the large (p20) and small (p10) subunits of an enzymatically 
active form of caspase-6. Abbreviations: FL, a full-length zymogen form of pro-caspase-6; p20p10, caspase-6 lacking the pro-domain; p20 
and p10, large and small subunits (respectively) of caspase-6 lacking the pro- and linker-domains; , an unidentified protein band, perhaps 
p20-linker (p23), pro-p20 (p23) or pro-p20-linker subunits of caspase-6 [152]. Data in A are presented as means ± SD (n = 3-4); *p<0.05; 
**p<0.01; ***p<0.001.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2
Goldberg AA et al. “Lithocholic bile acid …”         Figure 6
0 0 150 0
p10
β -actin
LCA (µM)
BE(2)-m17 SK-N-MCIXC
p20p10
125 250
Lan-1
B
125 100 100
A
C
a
s
p
a
s
e
-
6
(
V
E
I
D
a
s
e
)
 
a
c
t
i
v
i
t
y
 
(
p
m
o
l
/
µ
g
 
p
r
o
t
e
i
n
/
m
i
n
)
*
**
**
***
0    125  150    0    100  125    0    100   250
LCA (µM)
BE(2)-m17               
SK-n-MCIXC               
Lan-1
FL
p20
Oncotarget 2011; 2:  761 - 782 770 www.impactjournals.com/oncotarget
LCA  reduces  the  activity  of  the  inflammatory 
caspase-1 in two nb cell lines
In addition to its stimulatory effect on caspases-3, 
-6,  -8  and  -9,  LCA  significantly  reduced  caspase-1 
activity in NB cell lines BE(2)-m17 and SK-n-MCIXC, 
but  not  in  Lan-1  (Suppl.  Fig.  1).  Caspase-1  is  an 
inflammatory  caspase  that  drives  the  processing  and 
unconventional secretion of the cytokines interleukin-1β 
and interleukin-18 [159-162]. Following their secretion 
by mammalian cells, cytokines promote the growth and 
proliferation of neighbouring cells in the same tissue [163-
166]. Hence, it is tempting to speculate that by reducing 
caspase-1 activity in BE(2)-m17 and SK-n-MCIXC cells, 
and thereby impairing their ability to process and secrete 
cytokines, LCA could prevent growth and proliferation of 
neighbouring NB cells in culture.
lcA does not enter cultured nb cells
Our  mass  spectrometry-based  measurement  of 
cellular and extracellular levels of exogenously added LCA 
revealed that it does not enter BE(2)-m17, SK-n-MCIXC 
or Lan-1 cells (Suppl. Table 1). Thus, LCA selectively 
kills these cancer cells by binding to their surface and then 
initiating intracellular signaling cascades that cause their 
apoptotic (as in case of BE(2)-m17 and SK-n-MCIXC) or 
non-apoptotic (as in case of Lan-1) death. In BE(2)-m17 
and  SK-n-MCIXC  cells,  the  intracellular  signaling 
cascades triggered by LCA bound to their surface also 
reduce the activity of the inflammatory caspase-1.
lcA kills cultured human breast cancer (bc) 
and rat glioma (Gl) cells
In  addition  to  its  high  anti-tumor  efficacy  and 
specificity  in  several  NB  cell  lines,  LCA  displayed  an 
anti-tumor effect in two other types of cultured cancer 
cells. In fact, treatment of the drug-sensitive human BC 
cell line MCF7 with LCA demonstrated a dose-dependent 
killing effect, as measured by the MTT cell viability assay 
(Suppl.  Fig.  2A). Treatment  with  1  μg/ml  doxorubicin 
demonstrated that these BC cells were highly drug sensitive 
(Suppl. Fig. 2A). Importantly, killing of MCF7 cells with 
LCA was associated with DNA damage, as visualized with 
antibodies against phosphorylated histone H2AX (Suppl. 
Fig.  2B).  Once  cells  encounter  DNA  damage,  histone 
H2AX phosphorylation at sites of damage has been shown 
to initiate the chromatin response required for DNA repair 
[167]. This is believed to serve as a docking site for DNA 
repair enzymes. At doses as low as 25 and 50 μM LCA, 
increased phosphorylated H2AX could be visualized in 
MCF7 cells (Suppl. Fig. 2B). Since most of these BC 
cells remain viable at 50 μM LCA (Suppl. Fig. 2A), DNA 
damage likely precedes their killing by LCA. We also 
assessed the ability of LCA to kill the cultured rat GL cell 
line F98. These highly proliferative and invasive cancer 
cells have increased resistance to chemo- and radiation 
therapy [168]. We found that at a concentration of 100 
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Figure 7: lcA increases activity of the initiator caspase-8 in cultured human nb cell lines be(2)-m17 and sK-n-
McIXc (but not in lan-1). Specific activity of caspase-8 was measured as described in Materials and Methods and expressed in 
picomoles of fluorescent compound 7-amino-4-trifluoromethyl coumarin released per microgram of protein per minute, based on the linear 
range of the curve. Data are presented as means ± SD (n = 3-4); ***p<0.001.Oncotarget 2011; 2:  761 - 782 771 www.impactjournals.com/oncotarget
μM, LCA kills most F98 cells (Suppl. Fig. 3). Together, 
our findings imply that LCA has a broad anti-tumor effect 
on cultured cancer cells derived from different tissues and 
organisms.
dIscussIon
Mechanisms underlying an anti-tumor effect of 
lcA in human nb cell cultures
This study provides evidence that LCA, a bile acid 
that delays aging of quiescent and proliferating yeast, 
exhibits a potent and selective anti-tumor effect in cultured 
human NB cells. Our findings suggest a model for two 
mechanisms underlying such effect of LCA, as outlined 
below. Several aspects of this model remain hypothetical.
In  NB  cell  lines  BE(2)-m17  and  SK-n-MCIXC, 
LCA triggers both the intrinsic and extrinsic pathways of 
apoptosis by binding to the cell surface and initiating the 
intracellular cascades that cause cell death (Fig. 8A). LCA 
binding to the cell surface leads to MOMP by activating 
caspase-8,  which  in  turn  causes  MOMP  -  perhaps  by 
cleaving and activating BID. LCA may also stimulate 
TGR5, its only known receptor on the cell surface (see 
below),  which  may  then  transmit  a  MOMP-activating 
signal from the plasma membrane to mitochondria via 
the cAMP/PKA signaling pathway. LCA-induced MOMP 
may result in efflux of cytochrome c from mitochondria, 
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Figure 8: A model for a mechanism underlying an anti-tumor effect of lcA in cultured human nb cell lines be(2)-m17 
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thereby causing apoptosome formation and the observed 
caspase-9 activation. Caspase-9 then activates caspase-3 
by proteolytically processing pro-caspase-3. The 
proteolytic activation of caspase-3 is also carried out 
by caspase-8 operating in the LCA-induced extrinsic 
pathway of apoptosis. Active caspase-3 completes the 
demolition phase of the LCA-driven apoptotic program 
by cleaving its protein substrates. Furthermore, LCA 
binding to the cell surface leads to proteolytic activation 
of caspase-6; the mechanism underlying such activation 
(either self-cleavage or proteolytic processing by active 
caspase-3) and the involvement of caspase-6 in LCA-
driven apoptosis remain to be established. Moreover, 
LCA binding to the cell surface causes inhibition of the 
inflammatory caspase-1. Such inhibition may contribute 
to the anti-tumor effect of LCA by attenuating the 
processing  and  secretion  of  the  cytokines  interleukin-
1β  and  interleukin-18,  thereby  preventing  growth  and 
proliferation of neighbouring NB cells in culture.
Recent  findings  suggest  the  following  cascade  of 
events leading to the above described activation of both 
the intrinsic and extrinsic apoptotic pathways in response 
to LCA binding to the surface of BE(2)-m17 and SK-
n-MCIXC cells. The only known LCA receptor on the 
cell surface in rodents and humans is TGR5, a member 
of the G-protein coupled receptor family [169,170]. 
LCA is the most potent natural agonist of TGR5, with 
EC50  of  530  nM  [171,172].  Importantly,  TGR5  has 
been shown to be expressed in neurons [170,173-175]. 
LCA-stimulated  TGR5  could  initiate  three  molecular 
cascades that trigger the intrinsic and extrinsic pathways 
of apoptotic cell death (Fig. 8B). First, it could initiate 
the cAMP/PKA signaling pathway known to response by 
altering oxidation-reduction processes in mitochondria 
and mitochondrial morphology [169,170,176-178]. The 
resulting changes in mitochondria may include such well-
documented  effects  of  LCA  as  MOMP  activation  and 
elevated  ROS  production  [169,170,176-178].  Second, 
the elevated in response to LCA intracellular ROS could 
intensify  vesicle-mediated  trafficking  of  the  CD95/Fas 
death receptor monomers from the Golgi to the plasma 
membrane, another well-documented effect of LCA in 
human  cells  [179,180].  Third,  LCA-stimulated  TGR5 
could activate the MEKK1/2/3-MKK4/7 protein kinase 
cascade resulting in phosphorylation of c-Jun-N terminal 
kinase (JNK). Such LCA/TGR5-driven phosphorylation 
has been shown to release pro-caspase-8 from a complex 
that  it  forms  with  unphosphorylated  JNK,  thereby 
enabling its recruitment to the CD95/Fas death-inducing 
signaling  complex  consisting  of  the  CD95/Fas  death 
receptor trimers and the adaptor Fas-Associated Death 
Domain [176,181]. Following pro-caspase-8 dimerization 
and proteolytic processing, its active form could trigger 
both the intrinsic and extrinsic apoptotic death pathways 
(Fig. 8A).
Our  findings  imply  that  a  different  mechanism 
underlies the anti-tumor effect of LCA in cultured 
human NB cell line Lan-1. We propose such effect of 
LCA in Lan-1 is due to its ability to cause necrotic or 
some  other  non-apoptotic  kind  of  death,  which  is  not 
characterized by such major hallmark events of apoptosis 
as nuclear condensation and fragmentation, mitochondrial 
fragmentation and inner membrane depolarization, and 
activation of caspases-3, -6, -8 and -9.
A reason for the observed difference in the 
mechanisms by which LCA kills different NB cell lines 
(i.e., by triggering apoptotic cell death of BE(2)-m17 and 
SK-n-MCIXC, but by causing non-apoptotic cell death 
of Lan-1) remains to be established. All these cell lines 
exhibit amplified expression of the MYCN gene [96-98] 
and deletion of the short arm of chromosome 1p [100-
104]. However, the level of an anti-apoptotic member of 
the B-cell lymphoma-2 (BCL-2) protein family containing 
four BCL-2 homology (BH) domains in BE(2)-m17 is 
significantly  lower  than  that  in  Lan-1  [182]. The  anti-
apoptotic  BCL-2  proteins  prevent  MOMP  [183,184]. 
Therefore,  it  is  conceivable  that  the  lower  efficacy  of 
MOMP prevention in BE(2)-m17 makes this cell line more 
susceptible to LCA-induced apoptosis (which involves 
MOMP activation) than Lan-1. Furthermore, it is plausible 
that, due to the relatively high level of the anti-apoptotic 
BCL-2 protein with four BH domains in Lan-1, this cell 
line is more susceptible (as compared to BE(2)-m17) to a 
MOMP-independent kind of LCA-induced non-apoptotic 
cell death.
Another  kind  of  dissimilarity  between  different 
NB cell lines consists in lower activity of caspase-1 in 
BE(2)-m17  and  SK-n-MCIXC  cells  (as  compared  to 
that in Lan-1 cells) that have not been exposed to LCA; 
importantly,  LCA  further  and  significantly  reduces  the 
activity of this inflammatory caspase in BE(2)-m17 and 
SK-n-MCIXC,  but  not  in  Lan-1  (Suppl.  Fig.  1).  This 
observation  suggests  that  certain  pro-inflammatory 
alterations (including elevated activity of caspase-1) in 
NB cells may play an anti-apoptotic, cytoprotective role. 
It is conceivable therefore that the lower activities of 
caspase-1  in  BE(2)-m17  and  SK-n-MCIXC  (especially 
following their exposure to LCA) make these NB cell lines 
more susceptible to LCA-induced apoptosis than Lan-
1, in which a relatively high activity of caspase-1 is not 
reduced by LCA. Of note, recent findings in mice imply 
that certain mild pro-inflammatory alterations, including 
increased  mitochondrial  ROS  and  elevated  expression 
of inflammatory cytokines, can extend animal longevity 
[185,186].Oncotarget 2011; 2:  761 - 782 773 www.impactjournals.com/oncotarget
lcA modulates mitochondrial structure and 
function to cause an anti-tumor effect in cultured 
human nb cells and an anti-aging effect in 
quiescent yeast
This study as well as our published [86] and recent 
unpublished data suggest that both an anti-tumor effect 
of LCA in cultured human NB cells and its longevity-
extending effect in quiescent yeast are due to its ability 
to  modulate  mitochondria-confined  processes  playing 
essential roles in both cancer and aging. Interestingly, 
the effects of LCA on these mitochondrial processes 
seen in NB cell cultures are opposite of those observed 
in quiescent yeast and, for some processes, in primary 
cultures of human neurons. Indeed, while LCA enhances 
the susceptibility of NB cell lines BE(2)-m17 and SK-
n-MC to mitochondria-controlled apoptotic cell death 
caused by exogenously added hydrogen peroxide (Fig. 2), 
it significantly increases the resistance of quiescent yeast 
[86] and primary cultures of human neurons (Fig. 2) to 
such a form of cell death. Furthermore, while LCA causes 
the  fragmentation  of  a  tubular  mitochondrial  network 
into  individual  mitochondria  in  BE(2)-m17  and  SK-n-
MC (Figs. 4A and 4B), it attenuates such mitochondrial 
fragmentation in quiescent yeast [86]. Moreover, LCA 
triggers the complete dissipation of the electrochemical 
potential across the inner mitochondrial membrane 
in  BE(2)-m17  and  SK-n-MC  (Figs.  4C  and  4D).  In 
contrast, although exposure of yeast cells to LCA causes a 
reduction of such potential by 50% upon entry into a non-
proliferative state [86], for a long time after becoming 
quiescent these cells maintain higher mitochondrial 
transmembrane potential than their quiescent counterparts 
that have not been exposed to LCA (Beach et al., 
manuscript in preparation). To the best of our knowledge, 
these findings provide the first example of a compound 
that can kill cancer cells and increase longevity of non-
cancerous cells by causing quite opposite effects on the 
same kind of mitochondria-confined processes in these 
two different cell types. A key challenge for the future will 
be to understand why mitochondria in cancer and non-
cancerous cells respond so differently to LCA exposure.
A broad anti-tumor effect of lcA
This study demonstrates that, in addition to the high 
anti-tumor efficacy and specificity exhibited by LCA in 
several NB cell lines, this bile acid displays an anti-tumor 
effect in human BC and rat GL cells. Future studies will 
examine if mechanisms underlying such broad anti-tumor 
effect of LCA are similar in cultured cancer cells that 
originate from different tissues and organisms.
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MAterIAls And MetHods
cell culture
Human NB cell lines were cultured in the following 
media:  1)  SK-n-MCIXC  and  BE(2)-m17  cells  in  a 
1:1  mixture  of  Dulbecco’s  Modified  Eagle’s  Medium 
(DMEM) and Ham’s F-12 Nutrient Mixture (Invitrogen/
Gibco BRL, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS) (HyClone, Logan, UT); 2) SK-n-SH 
cells  in  Eagle’s  Minimum  Essential  Medium  (EMEM) 
(Invitrogen/Gibco  BRL,  Carlsbad,  CA)  supplemented 
with 10% FBS; and 3) Lan-1 cells in DMEM (Invitrogen/
Gibco  BRL,  Carlsbad,  CA)  supplemented  with  10% 
bovine calf serum (BCS) (HyClone, Logan, UT). Human 
primary neurons were prepared from fetal cerebrum tissue 
and cultured as previously described [187], in accordance 
with the Canadian Institute of Health Research regulations 
and as approved by the McGill University Institutional 
Review Board. MCF7 human BC and F98 rat GL cell lines 
from American Type Culture Collection were cultured 
in  a  1:1  mixture  of  DMEM  and  Ham’s  F-12  Nutrient 
Mixture  (Sigma-Aldrich,  St  Louis,  MI)  supplemented 
with  10%  FBS  (Invitrogen/Gibco  BRL,  Carlsbad,  CA) 
and 1× anti-mycotic/anti-biotic (Invitrogen/Gibco BRL, 
Carlsbad, CA). All cell lines were cultured in a humidified 
atmosphere (5% CO2) at 37 °C.
treatment of cells with lcA, hydrogen peroxide 
or z-deVd-fmk
Stock solutions of LCA (Sigma-Aldrich, St Louis, 
MI) in varying concentrations were first made in 100% 
dimethyl  sulfoxide  (DMSO)  (Sigma-Aldrich,  St  Louis, 
MI). For treatment of cultured human NB, human BC 
and rat GL cells, these stock solutions were then diluted 
to  the  indicated  final  concentration  of  LCA  (the  final 
concentration of DMSO was always kept at 1%) in either 
a 1:1 mixture of DMEM and Ham’s F-12 Nutrient Mixture 
supplemented  with  10%  FBS  (for  SK-n-MCIXC  and Oncotarget 2011; 2:  761 - 782 774 www.impactjournals.com/oncotarget
BE(2)-m17 cells), EMEM supplemented with 10% FBS 
(for SK-n-SH cells), DMEM supplemented with 10% BCS 
(for Lan-1 cells) or a 1:1 mixture of DMEM and Ham’s 
F-12 Nutrient Mixture supplemented with 10% FBS and 
1X  anti-mycotic/anti-biotic  (for  MCF7  and  F98  cells). 
For treatment of human primary neurons with LCA, stock 
solutions of LCA in varying concentrations made in 100% 
DMSO were diluted in EMEM containing 0.225% sodium 
bicarbonate, 1 mM sodium pyruvate, 2 mM L-glutamine, 
0.1% dextrose (all from Life Technologies, Gaithersburg, 
MD) and 5% FBS (HyClone, Logan, UT) to the indicated 
final  concentration  of  LCA  (the  final  concentration 
of  DMSO  was  always  kept  at  1%).  For  treatment  of 
cultured cancer cells or primary neurons with LCA, they 
were incubated for 48 hours in the presence LCA at the 
indicated final concentrations; control cells were treated 
with an empty DMSO vehicle only. For cell treatment 
with hydrogen peroxide, its 30% stock solution (Fisher 
Scientific, Waltham, MA) was diluted in sterile H2O and 
added directly to the cell cultures after 24 h of their pre-
treatment with LCA or an empty DMSO vehicle only; cells 
were then incubated for 24 h. In experiments involving 
cell treatment with z-DEVD-fmk, this caspase-3 inhibitor 
was added to a final concentration of 5 μM simultaneously 
with LCA or an empty DMSO vehicle only.
cell viability assays
The number of viable cells in cultures exposed to LCA 
was measured using the MTT (3-(4,5-dimethylthiozol-2-
yl)-2,5-diphenyltetrazolium bromide)-based CellTiter 
96 Non-Radioactive Cell Proliferation Assay (Promega, 
Madison, WI). In this assay, only viable, metabolically 
active cells were able to reduce the yellow tetrazolium salt 
of MTT to form a purple formazan product. This insoluble 
product was solubilized by the addition of a detergent. The 
resulting intracellular purple formazan was then detected 
spectrophotometrically using a 96-well plate reader at 
a wavelength of 570 nm. The signal was corrected to 
account for cellular debris using a wavelength of 630 
nm. Chromatin in cells exposed to LCA and/or hydrogen 
peroxide  and/or  z-DEVD-fmk  was  visualized  with  the 
fluorescent dye Hoechst used at a final concentration of 
4  μM  in  culture  media  and  viewed  using  fluorescence 
microscopy. For each cell culture, the percentage of viable 
non-apoptotic cells carrying intact, non-fragmented nuclei 
containing non-condensed chromatin was calculated. 
Dead apoptotic cells carried fragmented nuclei containing 
condensed chromatin, a hallmark event of apoptotic death.
Visualization of mitochondria and measurement 
of the mitochondrial membrane potential by 
fluorescence microscopy
Mitochondrial morphology of cells treated with 
LCA  was  visualized  using  MitoTracker  Red  CMXRos 
(Molecular Probes, San Diego, CA) used at a concentration 
of 125 nM in the culture media. Cells were viewed using 
fluorescence  microscopy,  and  the  percentage  of  cells 
displaying fragmented mitochondria was calculated. The 
mitochondrial  membrane  potential  (∆Ψ)  was  measured 
using tetramethylrhodamine ethyl ester (TMRE), a cell-
permeant, cationic fluorescent dye. The extent of reversible 
sequestration of TMRE by mitochondria is proportional 
to the value of ∆Ψ. Cells were incubated with 50 nM 
TMRE for 20 min and directly viewed using fluorescence 
microscopy.  The  percentage  of  TMRE-positive  cells 
displaying a detectable level of ∆Ψ was calculated.
Fluorescence microscopy
For  all  cells  and  fluorescent  dyes,  images  were 
collected  with  a  Nikon  Eclipse  (TE2000-U)  inverted 
fluorescence microscope under 20 × magnification. A filter 
cube with an excitation wavelength of 330-380 nm was 
used to visualize Hoechst-stained cells. Cells stained with 
MitoTracker  Red  CMXRos  or  TMRE  were  visualized 
using filter cubes with excitations of 590-650 nm or 532-
587 nm, respectively.
caspase activity assays
Proteins were extracted from harvested cells using 
an ice-cold lysis buffer containing 50 mM HEPES, 0.1% 
CHAPS, 0.1 mM EDTA and protease inhibitors (0.1μg/
ml TLCK, 0.5 μg/ml leupeptin, 38 mg/ml AEBSF, 0.1 
μg/ml  pepstatin A). The  cell  lysate  was  centrifuged  at 
13,000 × g for 5 min at 4oC to remove cell debris and 
any detergent-insoluble proteins. The supernatant was 
collected and frozen at -80oC. Extracts were thawed and 
protein  concentrations  were  quantified  with  the  Pierce 
BCA protein assay (Thermo Scientific, Waltham, MA). 
The extracts were then assayed for caspase activities 
using  fluorogenic  substrates  specific  for  caspase-1  (10 
μM Ac-YVAD-AFC), caspase-3 (5 μM Ac-DEVD-AFC), 
caspase-6  (10  μM  Ac-VEID-AFC),  caspase-8  (10  μM 
Ac-IETD-AFC) or caspase-9 (10 μM Ac-LEHD-AFC) in 
caspase reaction buffer (20 mM PIPES, pH 7.2, 30 mM 
NaCl, 10 mM DTT, 1 mM EDTA, 0.1% CHAPS, 10% 
sucrose). The time-dependent release of the fluorescent 
compound  7-amino-4-trifluoromethyl  coumarin  (AFC) 
was monitored using a Bio-Rad Fluoromark fluorometer 
(Hercules, CA) at an excitation wavelength of 390 nm and 
an emission wavelength of 538 nm. Measurements were 
recorded at 2 min intervals for 1 h. A standard curve of AFC 
fluorescence was used to calculate AFC (in picomoles) 
released in the reactions. Specific activities were expressed 
as picomoles of AFC released per microgram of protein 
per minute, based on the linear range of the curve.Oncotarget 2011; 2:  761 - 782 775 www.impactjournals.com/oncotarget
Pro-caspase-3 and pro-caspase-6 cleavage assays
50 μg of protein from crude cellular extracts were 
resolved  by  SDS-PAGE  in  a  15%  polyacrylamide  gel 
and then transferred to a PVDF Immobilon-P membrane 
(Millipore, Bedford, MA). Following wash with 5% 
milk,  blots  were  incubated  with  primary  antibodies 
used at the following dilutions: 1:500 for anti-cleaved-
caspase-3 p17 (Cell Signaling, Beverly, MA), 1:250 for 
anti-cleaved-caspase-6 p10 (Pharmingen, San Diego, CA) 
and 1:5,000 for anti-β-Actin (Sigma-Aldrich, St Louis, 
MI). Immunoreactivity was visualized with horseradish 
peroxidase-conjugated secondary antibodies (Amersham, 
Oakville, ON) that were used at dilutions 1:2,000 (for 
anti-rabbit) and 1:5,000 (for anti-mouse), respectively. 
Antigen-antibody complexes were detected by enhanced 
chemiluminescence using an ECL plus chemiluminescence 
Western blot detection reagents (Amersham Pharmacia 
Biotech, Piscataway, NJ).
Histone H2AX phosphorylation assay
BC cells were removed from 100-mm tissue 
culture dishes using a rubber policeman and ice-cold 
phosphate-buffered saline (PBS). The cells were pelleted 
by centrifugation at 3,000 rpm at 4oC. The pellets were 
resuspended in ice-cold lysis buffer (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 0.5 mM EDTA, 0.1 mM EGTA, 0,1% 
NP-40, 1× mammalian cell anti-protease cocktail (Sigma-
Aldrich,  St  Louis,  MI)).  The  cells  were  lysed  using 
multiple freeze-thaw cycles followed by pulse sonication 
on ice and centrifugation at 3,000 rpm for 5 min at 40 
C to remove cell debris. Western blot analysis of these 
protein lysates was performed as previously described 
[188].  Briefly,  equivalent  amounts  of  protein  (assessed 
using  Bio-Rad  Protein  Reagent;  Bio-Rad  Laboratories, 
Hercules, CA) were resolved on 10% SDS-PAGE gels. 
Following electrophoresis the proteins were trans-blotted 
onto nitrocellulose membranes (Pall-VWR International, 
Radnor, PA). The membranes were blocked overnight at 
4o C on a gyratory plate with 5% molecular grade skim 
milk  powder  (Bio-Rad  Laboratories,  Hercules,  CA)  in 
PBS  containing  0.1%  Tween-20  (PBST).  Primary  and 
secondary antibody incubations and subsequent washes 
were carried out in the same buffer. The antibody to 
phosphorylated  H2AX  was  obtained  from  Santa  Cruz 
Biotechnology (Santa Cruz, CA). The primary antibody 
for  GAPDH  was  purchased  from  Sigma-Aldrich  (St 
Louis, MI). Secondary HRP antibodies were purchased 
from Bio-Rad Laboratories (Hercules, CA). Blots were 
immunoprobed overnight with primary antibodies used at 
a 1:1,000 dilution. Secondary HRP antibody was applied 
at room temperature on a gyratory plate at a 1:10,000 
dilution for 30 min. Following multiple washes, an 
enhanced chemiluminescence detection system (DuPont-
NEN; Boston, MA) was used to detect the target antigen/
antibody complexes. Blots were then stripped at 50o C for 
30 min in a Tris-buffered 20% SDS/1% 2-mercaptoethanol 
stripping solution, washed and reprobed with GAPDH 
antibody to verify protein loading equivalency.
Mass spectrometric measurement of lcA
Mass spectrometry-based quantitative analysis of 
LCA was performed as previously reported [189]. In 
brief, lipids were extracted by a modified Bligh and Dyer 
method [189] from cells pelleted by centrifugation for 
5 min at 16,000 × g at 4oC and from the supernatant of 
cultural medium. The extracted lipids were dried under 
nitrogen and resuspended in chloroform. Immediately 
prior to injection the extracted lipids were combined 
with a 2:1 methanol:chloroform mixture supplemented 
with 0.1% (v/v) ammonium hydroxide. The sample was 
injected  directly  into  a  Q-TOF  2  mass  spectrometer 
(Waters, Milford, MA) using a nano-ESI spray source at 1 
µl/min. Spectra were obtained in a negative-ion mode. The 
cone voltage was set to 30 v, the capillary voltage to 3.2 
kv and the collision gas to 10 (arbitrary units). Acquired 
spectra were centroided using the Masslynx software then 
deconvoluted and deisotoped with Excel macros.
statistical analysis
Statistical analysis was performed using Microsoft 
Excel’s  (2010)  Analysis  ToolPack-VBA.  All  data  are 
presented as the means ± SD. The p values were calculated 
using an unpaired two-tailed t test.
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